Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 195,841 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric Dube sold 195,841 shares of Travere Therapeutics stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $63.45, for a total value of $12,426,111.45. Following the completion of the transaction, the chief executive officer owned 432,886 shares in the company, valued at $27,466,616.70. The trade was a 31.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Up 2.0%

Shares of Travere Therapeutics stock opened at $64.74 on Friday. The stock’s fifty day moving average is $61.63 and its 200-day moving average is $48.50. The firm has a market capitalization of $6.10 billion, a PE ratio of -140.74 and a beta of 1.05. The company has a quick ratio of 3.99, a current ratio of 4.05 and a debt-to-equity ratio of 24.58. Travere Therapeutics, Inc. has a 12-month low of $22.06 and a 12-month high of $68.73.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.03. The business had revenue of $169.58 million during the quarter, compared to analyst estimates of $157.27 million. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.Travere Therapeutics’s revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter last year, the company posted $0.13 EPS. Equities analysts anticipate that Travere Therapeutics, Inc. will post -0.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TVTX. Jupiter Topco LLC acquired a new position in shares of Travere Therapeutics during the 2nd quarter worth $643,299,000. Bank of America Corp DE bought a new position in shares of Travere Therapeutics during the 2nd quarter valued at $259,527,000. Perceptive Advisors LLC lifted its stake in shares of Travere Therapeutics by 12.7% in the 4th quarter. Perceptive Advisors LLC now owns 4,278,180 shares of the company’s stock valued at $163,469,000 after purchasing an additional 483,565 shares during the last quarter. Geode Capital Management LLC increased its position in Travere Therapeutics by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,143,495 shares of the company’s stock worth $81,915,000 after buying an additional 5,465 shares during the last quarter. Finally, Stephens Investment Management Group LLC raised its holdings in Travere Therapeutics by 4.5% during the first quarter. Stephens Investment Management Group LLC now owns 1,798,466 shares of the company’s stock valued at $53,432,000 after buying an additional 76,843 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TVTX shares. Piper Sandler restated an “overweight” rating on shares of Travere Therapeutics in a report on Monday, August 17th. Wedbush lifted their price objective on shares of Travere Therapeutics from $61.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Wells Fargo & Company boosted their target price on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research note on Friday, June 12th. Canaccord Genuity Group increased their target price on Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings cut Travere Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $68.00.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

About Travere Therapeutics

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.